Exelixis Inc.
Exelixis, Inc. is a US oncology biotech focused on kinase inhibitors. Its FDA‑approved drugs CABOMETYX (renal cell carcinoma) and COMETRIQ (medullary thyroid cancer) anchor a pipeline that includes zanzalintinib and XL309, backed by Roche, BMS, and Takeda.
Headquarters: United States (USA)
- Website: Visit Site 🔗
- Type: Corporation
Company Profile
- Sector: Professional Services
- Industry: Biotechnology Research
- Employees: 1,147
- HQ: Alameda
Unlock the full potential.
Upgrade
Get access to Relative P/E Ratio Valuation Histogram.